Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and keeps an Overweight rating on the shares. The firm dropped the price target following analysis on the setrusumab COSMIC study. It still sees an over 70% chance of a positive study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges
- Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials
- Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth
- Ultragenyx price target lowered to $75 from $86 at TD Cowen
- Ultragenyx Reports Q3 2025 Financial Results